Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
The protease (PR) and virus infectivity factor (vif) gene sequences of a cohort of HIV-1 infected patients showing evidence of developing protease inhibitor (PI) resistance whilst undergoing highly active antiretroviral therapy (HAART) have been determined. The PR sequences showed the presence of the classical mutations associated with resistance to PIs. The sequence of the Vif protein showed less variation in samples from PI treated patients than in specimens prepared from treatment-naive patients. In addition a number of amino acid positions within Vif showed highly significant preferences for a particular amino acid in the PI-treated cohort compared to the untreated control cohort.
Adekale
Melanie A
MA
Department of Biological Sciences, University of Warwick, Coventry, United Kingdom.
Cane
Patricia A
PA
McCrae
Malcolm A
MA
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000494:pharmacology; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D016346:Gene Products, vif / Q000235:genetics*; D014644:Genetic Variation; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D016415:Sequence Alignment; D054320:vif Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D016346:Gene Products, vif; D017320:HIV Protease Inhibitors; D054320:vif Gene Products, Human Immunodeficiency Virus